Desethyl Dabigatran Etexilate Carboxamide | 1580491-16-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Desethyl Dabigatran Etexilate Carboxamide
• 英文别名: hexyl N-[4-[[5-[(3-amino-3-oxopropyl)-pyridin-2-ylcarbamoyl]-1-methylbenzimidazol-2-yl]methylamino]benzenecarboximidoyl]carbamate
• CAS: 1580491-16-2
• 化学式: C₃₂H₃₈N₈O₄
• 分子量: 598.7
• InChiKey: QQTDTILRFNZOGU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  44
• 可旋转键数：
  15
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  171
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• Dabigatran etexilate and related substances, processes and compositions, and use of the substances as reference standards and markers
  申请人：Medichem, S.A.

  公开号：EP2522662A1

  公开（公告）日：2012-11-14

  The present invention relates to dabigatran etexilate and related substances and use of the substances as reference standards and markers. There are also provided processes of detecting the substances in samples of dabigatran etexilate, or pharmaceutically acceptable salts or solvates thereof, and also for analyzing the purity of samples of dabigatran etexilate, or pharmaceutically acceptable salts or solvates thereof. There are still further provided processes of preparing dabigatran etexilate and related substances, and pharmaceutical compositions containing the same.

  本发明涉及达比加群酯和相关物质，以及将这些物质用作参考标准和标记物的用途。还提供了检测达比加群酯样品中这些物质的方法，或者这些样品的药用盐或溶剂，以及分析达比加群酯样品的纯度的方法。此外，还提供了制备达比加群酯和相关物质以及含有相同物质的药物组合物的方法。
• [EN] DABIGATRAN ETEXILATE AND RELATED SUBSTANCES, PROCESSES AND COMPOSITIONS, AND USE OF THE SUBSTANCES AS REFERENCE STANDARDS AND MARKERS<br/>[FR] ETÉXILATE DE DABIGATRAN ET SUBSTANCES, PROCÉDÉS ET COMPOSITIONS S'Y RAPPORTANT ET UTILISATION DES SUBSTANCES COMME ÉTALONS DE RÉFÉRENCE ET MARQUEURS
  申请人：MEDICHEM SA

  公开号：WO2012152855A1

  公开（公告）日：2012-11-15

  The present invention relates to dabigatran etexilate and related substances and use of the substances as reference standards and markers. There are also provided processes of detecting the substances in samples of dabigatran etexilate, or pharmaceutically acceptable salts or solvates thereof, and also for analyzing the purity of samples of dabigatran etexilate, or pharmaceutically acceptable salts or solvates thereof.There are still further provided processes of preparing dabigatran etexilate and related substances, and pharmaceutical compositions containing the same.

  本发明涉及达比加群酮乙酸酯及相关物质，以及将这些物质用作参考标准和标记物的用途。还提供了检测达比加群酮乙酸酯样品中这些物质的方法，或者其药学上可接受的盐或溶剂，以及分析达比加群酮乙酸酯样品纯度的方法。还提供了制备达比加群酮乙酸酯及相关物质的方法，以及含有这些物质的药物组合物。
• DABIGATRAN ETEXILATE AND RELATED SUBSTANCES, PROCESSES AND COMPOSITIONS, AND USE OF THE SUBSTANCES AS REFERENCE STANDARDS AND MARKERS
  申请人：Serra Miralles Judit

  公开号：US20140076036A1

  公开（公告）日：2014-03-20

  The present invention relates to dabigatran etexilate and related substances and use of the substances as reference standards and markers. There are also provided processes of detecting the substances in samples of dabigatran etexilate, or pharmaceutically acceptable salts or solvates thereof, and also for analyzing the purity of samples of dabigatran etexilate, or pharmaceutically acceptable salts or solvates thereof. There are still further provided processes of preparing dabigatran etexilate and related substances, and pharmaceutical compositions containing the same.

  本发明涉及达比加群酯和相关物质，以及将这些物质用作参考标准和标记的用途。还提供了检测达比加群酯或其药学上可接受的盐或溶剂的样品中这些物质的过程，以及分析达比加群酯或其药学上可接受的盐或溶剂的样品纯度的过程。还提供了制备达比加群酯和相关物质以及含有它们的制药组合物的过程。
• US9086390B2
  申请人：——

  公开号：US9086390B2

  公开（公告）日：2015-07-21
• [EN] PROCESS FOR THE PREPARATION OF DABIGATRAN ETEXILATE AND INTERMEDIATES THEREOF<br/>[FR] PROCÉDÉ DE PRÉPARATION D'ÉTÉXILATE DE DABIGATRAN ET SES INTERMÉDIAIRES
  申请人：GLENMARK PHARMACEUTICALS LTD GLENMARK GENERICS LTD

  公开号：WO2014041559A2

  公开（公告）日：2014-03-20

  The present invention provides a process for the preparation of dabigatran etexilate, a compound of Formula I or a salt thereof, in a purity of at least 99.0% and wherein the level of compound of formula X and XV is less than 0.15% w/w relative to the amount of dabigatran etexilate, a compound of Formula I or salt thereof, as determined by HPLC comprising; (a) subjecting a crude compound of formula I to treatment with alkyl acetate and ketone to form a mixture; (b) optionally heating the mixture; and (c) isolating the compound of Formula I.